The Science Behind EnteroBiotix

What is the microbiome?

The human digestive tract is home to one of the most dense and diverse microbial ecosystems in the known universe. These microbial communities, the habitat they live in, and their repertoire of activity are known collectively as the ‘gut microbiome’.

Studies show that imbalances in the gut microbiome are associated with a wide range of diseases and infections, ranging from the acute infection caused by the bacterium C.difficile, to complicated chronic conditions like obesity, liver disease and inflammatory bowel disease.

Many of these microbiome meditated conditions are challenging for doctors to treat. However, it is thought that it may be possible to alleviate symptoms or even cure patients by restoring order and balance to the gut microbiome through innovative medical therapies that contain live microorganisms.

What is Faecal Microbiota Transplantation (FMT)?

Faecal Microbiota transplantation (FMT) is a medical treatment that involves the transfer of microbial communities from one person into another with the intention of treating or preventing a disease. It is a National Institute for Health and Care Excellence (NICE) approved treatment for recurrent or resistant forms of C.difficile infection, with effectiveness of around 90% reported across several randomised controlled clinical trials. FMT has also shown promise in conditions beyond C.difficile infection, such as inflammatory bowel disease and irritable bowel syndrome.

Our Focus

We are harnessing the power of the human microbiome to develop novel medicinal products that restore health and prevent disease, with a specific focus on drug resistant bacterial infections.

We started EnteroBiotix after recognising that doctors who wished to perform FMT faced a number of difficulties, mainly relating to donor screening and product processing. To solve these problems and expand access to this potentially life saving treatment for patients, we established our minimally modified product portfolio, which are pre-screened and ready-to-use rigorously screened microbiota products available for use in FMT on a named patient basis.

To tackle the ever growing problem of antibiotic resistant bacteria, we are combining healthy donor microbiota with novel precision antimicrobial medicinal products. We believe that these combined products have the potential to create a paradigm shift in the way doctors treat patients suffering from superbugs, with a completely novel and unique dual mechanism of action.

Our Platform

EnteroBiotix is well positioned to drive progress in the field with differentiated drug discovery and state-of-the-art, MHRA licensed manufacturing capabilities.